Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer

Next Previous
Trial Profile

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Gilead Sciences; Immunomedics

    • Most Recent Events

    • 09 Dec 2023 Results of pooled analysis from TROPiCS-02, IMMU-132-01, and ASCENT presented at the 46th Annual San Antonio Breast Cancer Symposium.
    • 07 Jun 2022 Results assessing relationships between exposure of SG, free SN-38, and total antibody (tAB) following SG administration and its efficacy and safety outcomes were evaluated in patients with mTNBC from phase 1/2 IMMU-132-01 study and phase 3 ASCENT study, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Mar 2022 Data from IMMU132-01, IMMU132-05, and IMMU132-06 clinical trials were used to Impact of Udp-Glucuronosyl Transferase 1A1 Polymorphisms on the Pharmacokinetics of Sacituzumab Govitecan presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top